Domvanalimab Combination Shows Clinically Meaningful Progression-Free Survival in Lung Cancer
December 1st 2022Data from the fourth interim analysis of the ARC-7 trial shows that a combination of Fc-silent anti-TIGIT and anti-PD-1 molecules are effective for objective response rates in certain lung cancers.
Read More
FDA Approves First-in-Class Microbiota-Based Live Biotherapeutic for C. Difficile Infection
December 1st 2022Live-jslm (Rebyota; Ferring Pharmaceuticals) is indicated for the prevention of recurring Clostridioides difficile infection among patients 18 years of age and older after an antibiotic treatment.
Read More